Results 121 to 130 of about 306 (158)
Some of the next articles are maybe not open access.
2017
Abstract This chapter discusses tyrosinemia, including the biochemical and clinical abnormalities associated with tyrosinemia type I, tyrosinemia type II, tyrosinemia type III, hawkinsinuria, and alkaptonuria. Factors to be considered in nutritional intervention, such as energy requirements, a diet low in phenylalanine and tyrosine, and ...
Francjan van Spronsen, Margreet van Rijn
openaire +2 more sources
Abstract This chapter discusses tyrosinemia, including the biochemical and clinical abnormalities associated with tyrosinemia type I, tyrosinemia type II, tyrosinemia type III, hawkinsinuria, and alkaptonuria. Factors to be considered in nutritional intervention, such as energy requirements, a diet low in phenylalanine and tyrosine, and ...
Francjan van Spronsen, Margreet van Rijn
openaire +2 more sources
Pediatric and Developmental Pathology, 2001
Hypertyrosinemia encompasses several entities, of which tyrosinemia type I (or hepatorenal tyrosinemia, HT1) results in the most extensive clinical and pathological manifestations involving mainly the liver, kidney, and peripheral nerves. The clinical findings range from a severe hepatopathy of early infancy to chronic liver disease and rickets in the
P A, Russo, G A, Mitchell, R M, Tanguay
openaire +2 more sources
Hypertyrosinemia encompasses several entities, of which tyrosinemia type I (or hepatorenal tyrosinemia, HT1) results in the most extensive clinical and pathological manifestations involving mainly the liver, kidney, and peripheral nerves. The clinical findings range from a severe hepatopathy of early infancy to chronic liver disease and rickets in the
P A, Russo, G A, Mitchell, R M, Tanguay
openaire +2 more sources
2005
Abstract In 1932 the term tyrosinemia was first used to describe a single patient with constant urinary excretion of large quantities of tyrosine and the tyrosine metabolites, p-hydroxy phenyllactic (p-HPLA) and p-hydroxy phenylpyruvic acids (p-HPPA),1 which together are called tyrosyluria.
Rebecca Roberts +3 more
openaire +1 more source
Abstract In 1932 the term tyrosinemia was first used to describe a single patient with constant urinary excretion of large quantities of tyrosine and the tyrosine metabolites, p-hydroxy phenyllactic (p-HPLA) and p-hydroxy phenylpyruvic acids (p-HPPA),1 which together are called tyrosyluria.
Rebecca Roberts +3 more
openaire +1 more source
Hyperphenylalaninemias and Tyrosinemias
Clinics in Perinatology, 1976Discussion of the hyperphenylalaninemias include aspects such as incidence, inheritance, biochemical and clinical features, detection, differential diagnosis, treatment, and genetic counseling. Symptoms and treatment of neonatal tyrosinemia are also elucidated.
openaire +2 more sources
Acta Paediatrica, 1969
SummaryThe clinical and biochemical findings in the case of an infant with hereditary tyrosinemia followed from birth have been reported. The child received a low protein diet from birth and a formula diet restricted in phenylalanine and tyrosine when the diagnosis was established at 54 days of age.
GÖRAN BODEGÅRD +4 more
openaire +1 more source
SummaryThe clinical and biochemical findings in the case of an infant with hereditary tyrosinemia followed from birth have been reported. The child received a low protein diet from birth and a formula diet restricted in phenylalanine and tyrosine when the diagnosis was established at 54 days of age.
GÖRAN BODEGÅRD +4 more
openaire +1 more source
American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2006
AbstractThe genetic tyrosinemias are characterized by the accumulation of tyrosine in body fluids and tissues. The most severe form of tyrosinemia, Type I, is a devastating disorder of childhood that causes liver failure, painful neurologic crises, rickets, and hepatocarcinoma.
openaire +2 more sources
AbstractThe genetic tyrosinemias are characterized by the accumulation of tyrosine in body fluids and tissues. The most severe form of tyrosinemia, Type I, is a devastating disorder of childhood that causes liver failure, painful neurologic crises, rickets, and hepatocarcinoma.
openaire +2 more sources
NONTRANSPLANT TREATMENT OF TYROSINEMIA
Clinics in Liver Disease, 2000NTBC treatment has greatly improved the survival of patients with acute tyrosinemia and has reduced the need for liver transplantation during early childhood. In patients in whom treatment with NTBC was started early in life, 2 cases (1%) of HCC have occurred during the first year of treatment, but no further cases have occurred among these patients ...
E, Holme, S, Lindstedt
openaire +2 more sources
Tyrosinemia: The Quebec experience
Early Human Development, 1997Tyrosinemia, a genetic disorder of the liver and kidneys, is caused by reduced activity of fumarylacetoacetate hydrolase (FAH), the final enzyme in the degradation of tyrosine. The consequent presence of succinylacetone in urine or blood is pathognomonic of tyrosinemia and is used as a confirmatory test in the Quebec neonaral screening program.
openaire +2 more sources